The European Commission has granted conditional marketing authorization (Aic) for idecabtagene vicleucel (Ide-cel), the first T-cell based immunotherapy with chimeric antigen receptor (Car-T) directed against maturation antigen B cell (Bcma), for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and who have demonstrated disease progression to the last therapy. This was announced by Bristol Myers Squibb (Bms), noting that Ide-cel is the first and only approved Car-T therapy aimed at recognizing and binding to Bcma, a protein almost universally expressed on multiple myeloma cells, killing diseased cells.
Read Also
- Salus Tv n.33 of 18 August 2021 Aug 19, 2021
- Attention to the return of fake news on the ticks Jun 30, 2020
- Rennes: The biggest fest-noz in the world returns after two years of absence Nov 19, 2022
- WHO identifies pathogens that may cause future pandemics Nov 21, 2022
- Scientists have discovered how very different pressure on different hands Aug 6, 2020
- Health, the neurologist: ‘Telemedicine, innovation for multiple sclerosis patients’ Sep 6, 2021
- WHO: Monkeypox will not be a pandemic; there are still unknowns May 31, 2022